The LOX family has been known to promote fibrosis and tumorigenesis, and accumulated evidence supports the use of β‐aminopropionitrile (βAPN) and simtuzumab to inhibit LOX and LOX‐L2 activities in fibrosis and cancer 13. This evidence concerns the gene LOXL2 and cancer.